|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson
gptkb:Boehringer_Ingelheim
|
|
gptkbp:acquired
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:acquisition
|
gptkb:2017
|
|
gptkbp:ceo
|
gptkb:Martine_Clozel
|
|
gptkbp:clinical_trial
|
conducts clinical trials for new drugs
|
|
gptkbp:employees
|
approximately 2,000
|
|
gptkbp:focus_area
|
pulmonary arterial hypertension
|
|
gptkbp:founded
|
gptkb:1997
|
|
gptkbp:founder
|
gptkb:Jean-Paul_Clozel
|
|
gptkbp:headquarters
|
gptkb:Allschwil,_Switzerland
|
|
gptkbp:healthcare
|
develops pharmaceuticals for serious diseases
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Actelion
|
|
gptkbp:market
|
global market
|
|
gptkbp:partnerships
|
collaborates with various research institutions
|
|
gptkbp:products
|
gptkb:Opsumit
gptkb:Tracleer
gptkb:Uptravi
|
|
gptkbp:research_and_development
|
focus on rare diseases
|
|
gptkbp:research_areas
|
cardiovascular diseases
|
|
gptkbp:revenue
|
$2.1 billion (2016)
|
|
gptkbp:stock_exchange
|
gptkb:Swiss_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Actelion_Pharmaceuticals_Ltd.
|
|
gptkbp:website
|
www.actelion.com
|